nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A4—Temozolomide—melanoma	0.064	0.325	CbGbCtD
Paliperidone—CYP2D6—Vemurafenib—melanoma	0.0551	0.28	CbGbCtD
Paliperidone—CYP3A4—Vemurafenib—melanoma	0.035	0.178	CbGbCtD
Paliperidone—CYP3A5—Docetaxel—melanoma	0.0308	0.157	CbGbCtD
Paliperidone—HTR1D—meninx—melanoma	0.028	0.412	CbGeAlD
Paliperidone—CYP3A4—Docetaxel—melanoma	0.012	0.061	CbGbCtD
Paliperidone—HTR2A—hindlimb—melanoma	0.0033	0.0487	CbGeAlD
Paliperidone—HTR1B—blood vessel—melanoma	0.00328	0.0483	CbGeAlD
Paliperidone—HTR1D—blood vessel—melanoma	0.00318	0.0468	CbGeAlD
Paliperidone—HTR2A—appendage—melanoma	0.00283	0.0417	CbGeAlD
Paliperidone—HTR2A—endothelium—melanoma	0.00171	0.0252	CbGeAlD
Paliperidone—DRD3—head—melanoma	0.00171	0.0252	CbGeAlD
Paliperidone—HTR1D—eye—melanoma	0.00169	0.0249	CbGeAlD
Paliperidone—HTR2A—blood vessel—melanoma	0.00158	0.0232	CbGeAlD
Paliperidone—ADRA1B—head—melanoma	0.00131	0.0193	CbGeAlD
Paliperidone—DRD2—eye—melanoma	0.00127	0.0187	CbGeAlD
Paliperidone—DRD2—retina—melanoma	0.00126	0.0186	CbGeAlD
Paliperidone—DRD1—head—melanoma	0.00122	0.018	CbGeAlD
Paliperidone—HTR2A—neck—melanoma	0.00113	0.0166	CbGeAlD
Paliperidone—HRH1—eye—melanoma	0.00101	0.0148	CbGeAlD
Paliperidone—HTR1B—head—melanoma	0.000991	0.0146	CbGeAlD
Paliperidone—ADRA2C—mammalian vulva—melanoma	0.000982	0.0145	CbGeAlD
Paliperidone—HTR1D—head—melanoma	0.000959	0.0141	CbGeAlD
Paliperidone—HTR2C—head—melanoma	0.00095	0.014	CbGeAlD
Paliperidone—HTR2A—eye—melanoma	0.000839	0.0124	CbGeAlD
Paliperidone—HTR2A—retina—melanoma	0.000832	0.0123	CbGeAlD
Paliperidone—HTR1A—head—melanoma	0.0008	0.0118	CbGeAlD
Paliperidone—HRH1—mammalian vulva—melanoma	0.000797	0.0117	CbGeAlD
Paliperidone—ADRA2A—mammalian vulva—melanoma	0.000783	0.0115	CbGeAlD
Paliperidone—ADRA1A—head—melanoma	0.000737	0.0109	CbGeAlD
Paliperidone—DRD2—head—melanoma	0.000722	0.0106	CbGeAlD
Paliperidone—ADRA2C—head—melanoma	0.000702	0.0103	CbGeAlD
Paliperidone—Alopecia—Carmustine—melanoma	0.000674	0.00165	CcSEcCtD
Paliperidone—Angiopathy—Temozolomide—melanoma	0.000668	0.00164	CcSEcCtD
Paliperidone—Mental disorder—Carmustine—melanoma	0.000668	0.00164	CcSEcCtD
Paliperidone—Immune system disorder—Temozolomide—melanoma	0.000665	0.00163	CcSEcCtD
Paliperidone—Mediastinal disorder—Temozolomide—melanoma	0.000664	0.00163	CcSEcCtD
Paliperidone—Erythema—Carmustine—melanoma	0.000664	0.00163	CcSEcCtD
Paliperidone—Malnutrition—Carmustine—melanoma	0.000664	0.00163	CcSEcCtD
Paliperidone—Cough—Bleomycin—melanoma	0.000663	0.00163	CcSEcCtD
Paliperidone—Chills—Temozolomide—melanoma	0.000661	0.00162	CcSEcCtD
Paliperidone—Ill-defined disorder—Dactinomycin—melanoma	0.000658	0.00161	CcSEcCtD
Paliperidone—Anaemia—Dactinomycin—melanoma	0.000655	0.00161	CcSEcCtD
Paliperidone—Vomiting—Vemurafenib—melanoma	0.000651	0.0016	CcSEcCtD
Paliperidone—Alopecia—Temozolomide—melanoma	0.000651	0.0016	CcSEcCtD
Paliperidone—Dry skin—Docetaxel—melanoma	0.000649	0.00159	CcSEcCtD
Paliperidone—Chest pain—Bleomycin—melanoma	0.000647	0.00159	CcSEcCtD
Paliperidone—Myalgia—Bleomycin—melanoma	0.000647	0.00159	CcSEcCtD
Paliperidone—Orthostatic hypotension—Docetaxel—melanoma	0.000647	0.00158	CcSEcCtD
Paliperidone—Abdominal pain upper—Docetaxel—melanoma	0.000647	0.00158	CcSEcCtD
Paliperidone—Rash—Vemurafenib—melanoma	0.000646	0.00158	CcSEcCtD
Paliperidone—Mental disorder—Temozolomide—melanoma	0.000645	0.00158	CcSEcCtD
Paliperidone—Dermatitis—Vemurafenib—melanoma	0.000645	0.00158	CcSEcCtD
Paliperidone—Back pain—Carmustine—melanoma	0.000642	0.00157	CcSEcCtD
Paliperidone—Headache—Vemurafenib—melanoma	0.000642	0.00157	CcSEcCtD
Paliperidone—Erythema—Temozolomide—melanoma	0.000641	0.00157	CcSEcCtD
Paliperidone—Malnutrition—Temozolomide—melanoma	0.000641	0.00157	CcSEcCtD
Paliperidone—Breast disorder—Docetaxel—melanoma	0.00064	0.00157	CcSEcCtD
Paliperidone—Discomfort—Bleomycin—melanoma	0.000639	0.00157	CcSEcCtD
Paliperidone—Malaise—Dactinomycin—melanoma	0.000639	0.00157	CcSEcCtD
Paliperidone—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000638	0.00156	CcSEcCtD
Paliperidone—Leukopenia—Dactinomycin—melanoma	0.000635	0.00156	CcSEcCtD
Paliperidone—Nasopharyngitis—Docetaxel—melanoma	0.000633	0.00155	CcSEcCtD
Paliperidone—Dysgeusia—Temozolomide—melanoma	0.000628	0.00154	CcSEcCtD
Paliperidone—Confusional state—Bleomycin—melanoma	0.000626	0.00153	CcSEcCtD
Paliperidone—Vision blurred—Carmustine—melanoma	0.000625	0.00153	CcSEcCtD
Paliperidone—Alanine aminotransferase increased—Docetaxel—melanoma	0.000625	0.00153	CcSEcCtD
Paliperidone—Tremor—Carmustine—melanoma	0.000622	0.00152	CcSEcCtD
Paliperidone—Anaphylactic shock—Bleomycin—melanoma	0.00062	0.00152	CcSEcCtD
Paliperidone—Oedema—Bleomycin—melanoma	0.00062	0.00152	CcSEcCtD
Paliperidone—Back pain—Temozolomide—melanoma	0.00062	0.00152	CcSEcCtD
Paliperidone—Infection—Bleomycin—melanoma	0.000616	0.00151	CcSEcCtD
Paliperidone—Anaemia—Carmustine—melanoma	0.000613	0.0015	CcSEcCtD
Paliperidone—Dysphagia—Docetaxel—melanoma	0.000612	0.0015	CcSEcCtD
Paliperidone—Agitation—Carmustine—melanoma	0.00061	0.00149	CcSEcCtD
Paliperidone—Nausea—Vemurafenib—melanoma	0.000608	0.00149	CcSEcCtD
Paliperidone—Thrombocytopenia—Bleomycin—melanoma	0.000607	0.00149	CcSEcCtD
Paliperidone—Vision blurred—Temozolomide—melanoma	0.000604	0.00148	CcSEcCtD
Paliperidone—Myalgia—Dactinomycin—melanoma	0.000604	0.00148	CcSEcCtD
Paliperidone—Tremor—Temozolomide—melanoma	0.000601	0.00147	CcSEcCtD
Paliperidone—Discomfort—Dactinomycin—melanoma	0.000596	0.00146	CcSEcCtD
Paliperidone—Ill-defined disorder—Temozolomide—melanoma	0.000595	0.00146	CcSEcCtD
Paliperidone—Leukopenia—Carmustine—melanoma	0.000594	0.00146	CcSEcCtD
Paliperidone—Anaemia—Temozolomide—melanoma	0.000593	0.00145	CcSEcCtD
Paliperidone—Anorexia—Bleomycin—melanoma	0.000591	0.00145	CcSEcCtD
Paliperidone—Agitation—Temozolomide—melanoma	0.000589	0.00144	CcSEcCtD
Paliperidone—Angioedema—Temozolomide—melanoma	0.000586	0.00144	CcSEcCtD
Paliperidone—Hypotension—Bleomycin—melanoma	0.00058	0.00142	CcSEcCtD
Paliperidone—Oedema—Dactinomycin—melanoma	0.000579	0.00142	CcSEcCtD
Paliperidone—Malaise—Temozolomide—melanoma	0.000578	0.00142	CcSEcCtD
Paliperidone—Vertigo—Temozolomide—melanoma	0.000576	0.00141	CcSEcCtD
Paliperidone—Convulsion—Carmustine—melanoma	0.000575	0.00141	CcSEcCtD
Paliperidone—Infection—Dactinomycin—melanoma	0.000575	0.00141	CcSEcCtD
Paliperidone—Leukopenia—Temozolomide—melanoma	0.000574	0.00141	CcSEcCtD
Paliperidone—Hypertension—Carmustine—melanoma	0.000573	0.0014	CcSEcCtD
Paliperidone—Neutropenia—Docetaxel—melanoma	0.000572	0.0014	CcSEcCtD
Paliperidone—HRH1—head—melanoma	0.000571	0.0084	CbGeAlD
Paliperidone—Palpitations—Temozolomide—melanoma	0.000567	0.00139	CcSEcCtD
Paliperidone—Thrombocytopenia—Dactinomycin—melanoma	0.000567	0.00139	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Bleomycin—melanoma	0.000565	0.00139	CcSEcCtD
Paliperidone—Myalgia—Carmustine—melanoma	0.000565	0.00138	CcSEcCtD
Paliperidone—Chest pain—Carmustine—melanoma	0.000565	0.00138	CcSEcCtD
Paliperidone—Anxiety—Carmustine—melanoma	0.000563	0.00138	CcSEcCtD
Paliperidone—ADRA2A—head—melanoma	0.00056	0.00825	CbGeAlD
Paliperidone—Cough—Temozolomide—melanoma	0.00056	0.00137	CcSEcCtD
Paliperidone—Paraesthesia—Bleomycin—melanoma	0.000557	0.00137	CcSEcCtD
Paliperidone—Weight increased—Docetaxel—melanoma	0.000557	0.00137	CcSEcCtD
Paliperidone—Convulsion—Temozolomide—melanoma	0.000556	0.00136	CcSEcCtD
Paliperidone—Weight decreased—Docetaxel—melanoma	0.000554	0.00136	CcSEcCtD
Paliperidone—Hypertension—Temozolomide—melanoma	0.000554	0.00136	CcSEcCtD
Paliperidone—Dyspnoea—Bleomycin—melanoma	0.000553	0.00136	CcSEcCtD
Paliperidone—Anorexia—Dactinomycin—melanoma	0.000552	0.00135	CcSEcCtD
Paliperidone—Pneumonia—Docetaxel—melanoma	0.000549	0.00135	CcSEcCtD
Paliperidone—Confusional state—Carmustine—melanoma	0.000546	0.00134	CcSEcCtD
Paliperidone—Arthralgia—Temozolomide—melanoma	0.000546	0.00134	CcSEcCtD
Paliperidone—Myalgia—Temozolomide—melanoma	0.000546	0.00134	CcSEcCtD
Paliperidone—Infestation NOS—Docetaxel—melanoma	0.000546	0.00134	CcSEcCtD
Paliperidone—Infestation—Docetaxel—melanoma	0.000546	0.00134	CcSEcCtD
Paliperidone—Anxiety—Temozolomide—melanoma	0.000544	0.00133	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000542	0.00133	CcSEcCtD
Paliperidone—Oedema—Carmustine—melanoma	0.000542	0.00133	CcSEcCtD
Paliperidone—Discomfort—Temozolomide—melanoma	0.000539	0.00132	CcSEcCtD
Paliperidone—Decreased appetite—Bleomycin—melanoma	0.000539	0.00132	CcSEcCtD
Paliperidone—Infection—Carmustine—melanoma	0.000538	0.00132	CcSEcCtD
Paliperidone—Dry mouth—Temozolomide—melanoma	0.000534	0.00131	CcSEcCtD
Paliperidone—Jaundice—Docetaxel—melanoma	0.000532	0.0013	CcSEcCtD
Paliperidone—Pain—Bleomycin—melanoma	0.000531	0.0013	CcSEcCtD
Paliperidone—Conjunctivitis—Docetaxel—melanoma	0.00053	0.0013	CcSEcCtD
Paliperidone—Thrombocytopenia—Carmustine—melanoma	0.00053	0.0013	CcSEcCtD
Paliperidone—Tachycardia—Carmustine—melanoma	0.000529	0.0013	CcSEcCtD
Paliperidone—Confusional state—Temozolomide—melanoma	0.000528	0.00129	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000527	0.00129	CcSEcCtD
Paliperidone—Anaphylactic shock—Temozolomide—melanoma	0.000523	0.00128	CcSEcCtD
Paliperidone—Oedema—Temozolomide—melanoma	0.000523	0.00128	CcSEcCtD
Paliperidone—Infection—Temozolomide—melanoma	0.00052	0.00127	CcSEcCtD
Paliperidone—Anorexia—Carmustine—melanoma	0.000516	0.00127	CcSEcCtD
Paliperidone—Hepatobiliary disease—Docetaxel—melanoma	0.000516	0.00126	CcSEcCtD
Paliperidone—Epistaxis—Docetaxel—melanoma	0.000515	0.00126	CcSEcCtD
Paliperidone—Nervous system disorder—Temozolomide—melanoma	0.000513	0.00126	CcSEcCtD
Paliperidone—Thrombocytopenia—Temozolomide—melanoma	0.000512	0.00126	CcSEcCtD
Paliperidone—Feeling abnormal—Bleomycin—melanoma	0.000511	0.00125	CcSEcCtD
Paliperidone—Agranulocytosis—Docetaxel—melanoma	0.000509	0.00125	CcSEcCtD
Paliperidone—Skin disorder—Temozolomide—melanoma	0.000508	0.00125	CcSEcCtD
Paliperidone—Hypotension—Carmustine—melanoma	0.000506	0.00124	CcSEcCtD
Paliperidone—Decreased appetite—Dactinomycin—melanoma	0.000503	0.00123	CcSEcCtD
Paliperidone—Fatigue—Dactinomycin—melanoma	0.000499	0.00122	CcSEcCtD
Paliperidone—Anorexia—Temozolomide—melanoma	0.000499	0.00122	CcSEcCtD
Paliperidone—Pain—Dactinomycin—melanoma	0.000495	0.00121	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Carmustine—melanoma	0.000493	0.00121	CcSEcCtD
Paliperidone—Urticaria—Bleomycin—melanoma	0.000493	0.00121	CcSEcCtD
Paliperidone—ADRA2C—lymph node—melanoma	0.000492	0.00724	CbGeAlD
Paliperidone—Rhinitis—Docetaxel—melanoma	0.000491	0.0012	CcSEcCtD
Paliperidone—Body temperature increased—Bleomycin—melanoma	0.00049	0.0012	CcSEcCtD
Paliperidone—Insomnia—Carmustine—melanoma	0.00049	0.0012	CcSEcCtD
Paliperidone—Hypoaesthesia—Docetaxel—melanoma	0.000487	0.00119	CcSEcCtD
Paliperidone—Paraesthesia—Carmustine—melanoma	0.000486	0.00119	CcSEcCtD
Paliperidone—Urinary tract disorder—Docetaxel—melanoma	0.000484	0.00119	CcSEcCtD
Paliperidone—Dyspnoea—Carmustine—melanoma	0.000483	0.00118	CcSEcCtD
Paliperidone—Oedema peripheral—Docetaxel—melanoma	0.000483	0.00118	CcSEcCtD
Paliperidone—Somnolence—Carmustine—melanoma	0.000481	0.00118	CcSEcCtD
Paliperidone—Connective tissue disorder—Docetaxel—melanoma	0.000481	0.00118	CcSEcCtD
Paliperidone—Urethral disorder—Docetaxel—melanoma	0.00048	0.00118	CcSEcCtD
Paliperidone—Feeling abnormal—Dactinomycin—melanoma	0.000477	0.00117	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Temozolomide—melanoma	0.000477	0.00117	CcSEcCtD
Paliperidone—HTR2A—head—melanoma	0.000476	0.00702	CbGeAlD
Paliperidone—Insomnia—Temozolomide—melanoma	0.000473	0.00116	CcSEcCtD
Paliperidone—Gastrointestinal pain—Dactinomycin—melanoma	0.000473	0.00116	CcSEcCtD
Paliperidone—Decreased appetite—Carmustine—melanoma	0.000471	0.00115	CcSEcCtD
Paliperidone—Paraesthesia—Temozolomide—melanoma	0.00047	0.00115	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Carmustine—melanoma	0.000468	0.00115	CcSEcCtD
Paliperidone—Dyspnoea—Temozolomide—melanoma	0.000467	0.00114	CcSEcCtD
Paliperidone—Somnolence—Temozolomide—melanoma	0.000465	0.00114	CcSEcCtD
Paliperidone—Pain—Carmustine—melanoma	0.000463	0.00113	CcSEcCtD
Paliperidone—Constipation—Carmustine—melanoma	0.000463	0.00113	CcSEcCtD
Paliperidone—Dyspepsia—Temozolomide—melanoma	0.000461	0.00113	CcSEcCtD
Paliperidone—Eye disorder—Docetaxel—melanoma	0.000458	0.00112	CcSEcCtD
Paliperidone—Abdominal pain—Dactinomycin—melanoma	0.000457	0.00112	CcSEcCtD
Paliperidone—Body temperature increased—Dactinomycin—melanoma	0.000457	0.00112	CcSEcCtD
Paliperidone—Hypersensitivity—Bleomycin—melanoma	0.000457	0.00112	CcSEcCtD
Paliperidone—Decreased appetite—Temozolomide—melanoma	0.000455	0.00111	CcSEcCtD
Paliperidone—Flushing—Docetaxel—melanoma	0.000455	0.00111	CcSEcCtD
Paliperidone—Cardiac disorder—Docetaxel—melanoma	0.000455	0.00111	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Temozolomide—melanoma	0.000452	0.00111	CcSEcCtD
Paliperidone—Fatigue—Temozolomide—melanoma	0.000451	0.00111	CcSEcCtD
Paliperidone—Pain—Temozolomide—melanoma	0.000448	0.0011	CcSEcCtD
Paliperidone—Constipation—Temozolomide—melanoma	0.000448	0.0011	CcSEcCtD
Paliperidone—Feeling abnormal—Carmustine—melanoma	0.000446	0.00109	CcSEcCtD
Paliperidone—Asthenia—Bleomycin—melanoma	0.000445	0.00109	CcSEcCtD
Paliperidone—Angiopathy—Docetaxel—melanoma	0.000444	0.00109	CcSEcCtD
Paliperidone—Gastrointestinal pain—Carmustine—melanoma	0.000443	0.00109	CcSEcCtD
Paliperidone—Immune system disorder—Docetaxel—melanoma	0.000442	0.00108	CcSEcCtD
Paliperidone—Mediastinal disorder—Docetaxel—melanoma	0.000442	0.00108	CcSEcCtD
Paliperidone—Chills—Docetaxel—melanoma	0.00044	0.00108	CcSEcCtD
Paliperidone—Pruritus—Bleomycin—melanoma	0.000439	0.00108	CcSEcCtD
Paliperidone—CYP2D6—head—melanoma	0.000434	0.00639	CbGeAlD
Paliperidone—Alopecia—Docetaxel—melanoma	0.000433	0.00106	CcSEcCtD
Paliperidone—Feeling abnormal—Temozolomide—melanoma	0.000431	0.00106	CcSEcCtD
Paliperidone—Mental disorder—Docetaxel—melanoma	0.000429	0.00105	CcSEcCtD
Paliperidone—Abdominal pain—Carmustine—melanoma	0.000428	0.00105	CcSEcCtD
Paliperidone—Body temperature increased—Carmustine—melanoma	0.000428	0.00105	CcSEcCtD
Paliperidone—Gastrointestinal pain—Temozolomide—melanoma	0.000428	0.00105	CcSEcCtD
Paliperidone—Erythema—Docetaxel—melanoma	0.000426	0.00105	CcSEcCtD
Paliperidone—Malnutrition—Docetaxel—melanoma	0.000426	0.00105	CcSEcCtD
Paliperidone—Hypersensitivity—Dactinomycin—melanoma	0.000426	0.00104	CcSEcCtD
Paliperidone—Dysgeusia—Docetaxel—melanoma	0.000418	0.00102	CcSEcCtD
Paliperidone—Urticaria—Temozolomide—melanoma	0.000416	0.00102	CcSEcCtD
Paliperidone—Asthenia—Dactinomycin—melanoma	0.000415	0.00102	CcSEcCtD
Paliperidone—Body temperature increased—Temozolomide—melanoma	0.000414	0.00101	CcSEcCtD
Paliperidone—Abdominal pain—Temozolomide—melanoma	0.000414	0.00101	CcSEcCtD
Paliperidone—Back pain—Docetaxel—melanoma	0.000413	0.00101	CcSEcCtD
Paliperidone—Muscle spasms—Docetaxel—melanoma	0.00041	0.001	CcSEcCtD
Paliperidone—HRH1—lymph node—melanoma	0.000399	0.00588	CbGeAlD
Paliperidone—Hypersensitivity—Carmustine—melanoma	0.000399	0.000978	CcSEcCtD
Paliperidone—Diarrhoea—Dactinomycin—melanoma	0.000396	0.00097	CcSEcCtD
Paliperidone—Vomiting—Bleomycin—melanoma	0.000394	0.000967	CcSEcCtD
Paliperidone—Anaemia—Docetaxel—melanoma	0.000394	0.000966	CcSEcCtD
Paliperidone—ADRA2A—lymph node—melanoma	0.000392	0.00578	CbGeAlD
Paliperidone—Rash—Bleomycin—melanoma	0.000391	0.000959	CcSEcCtD
Paliperidone—Dermatitis—Bleomycin—melanoma	0.000391	0.000958	CcSEcCtD
Paliperidone—Asthenia—Carmustine—melanoma	0.000389	0.000952	CcSEcCtD
Paliperidone—Hypersensitivity—Temozolomide—melanoma	0.000386	0.000945	CcSEcCtD
Paliperidone—Syncope—Docetaxel—melanoma	0.000382	0.000937	CcSEcCtD
Paliperidone—Leukopenia—Docetaxel—melanoma	0.000382	0.000935	CcSEcCtD
Paliperidone—Palpitations—Docetaxel—melanoma	0.000377	0.000924	CcSEcCtD
Paliperidone—Asthenia—Temozolomide—melanoma	0.000375	0.00092	CcSEcCtD
Paliperidone—Loss of consciousness—Docetaxel—melanoma	0.000375	0.000919	CcSEcCtD
Paliperidone—Cough—Docetaxel—melanoma	0.000372	0.000912	CcSEcCtD
Paliperidone—Diarrhoea—Carmustine—melanoma	0.000371	0.000908	CcSEcCtD
Paliperidone—Pruritus—Temozolomide—melanoma	0.00037	0.000907	CcSEcCtD
Paliperidone—Convulsion—Docetaxel—melanoma	0.000369	0.000905	CcSEcCtD
Paliperidone—Nausea—Bleomycin—melanoma	0.000369	0.000903	CcSEcCtD
Paliperidone—Hypertension—Docetaxel—melanoma	0.000368	0.000902	CcSEcCtD
Paliperidone—Vomiting—Dactinomycin—melanoma	0.000368	0.000902	CcSEcCtD
Paliperidone—Rash—Dactinomycin—melanoma	0.000365	0.000894	CcSEcCtD
Paliperidone—Arthralgia—Docetaxel—melanoma	0.000363	0.00089	CcSEcCtD
Paliperidone—Chest pain—Docetaxel—melanoma	0.000363	0.00089	CcSEcCtD
Paliperidone—Myalgia—Docetaxel—melanoma	0.000363	0.00089	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000361	0.000884	CcSEcCtD
Paliperidone—Dizziness—Carmustine—melanoma	0.000358	0.000878	CcSEcCtD
Paliperidone—Diarrhoea—Temozolomide—melanoma	0.000358	0.000878	CcSEcCtD
Paliperidone—Dry mouth—Docetaxel—melanoma	0.000355	0.00087	CcSEcCtD
Paliperidone—Confusional state—Docetaxel—melanoma	0.000351	0.00086	CcSEcCtD
Paliperidone—Oedema—Docetaxel—melanoma	0.000348	0.000853	CcSEcCtD
Paliperidone—Anaphylactic shock—Docetaxel—melanoma	0.000348	0.000853	CcSEcCtD
Paliperidone—Dizziness—Temozolomide—melanoma	0.000346	0.000848	CcSEcCtD
Paliperidone—Infection—Docetaxel—melanoma	0.000346	0.000847	CcSEcCtD
Paliperidone—Vomiting—Carmustine—melanoma	0.000344	0.000844	CcSEcCtD
Paliperidone—Nausea—Dactinomycin—melanoma	0.000344	0.000842	CcSEcCtD
Paliperidone—Shock—Docetaxel—melanoma	0.000342	0.000839	CcSEcCtD
Paliperidone—Rash—Carmustine—melanoma	0.000341	0.000837	CcSEcCtD
Paliperidone—Nervous system disorder—Docetaxel—melanoma	0.000341	0.000836	CcSEcCtD
Paliperidone—Dermatitis—Carmustine—melanoma	0.000341	0.000836	CcSEcCtD
Paliperidone—Thrombocytopenia—Docetaxel—melanoma	0.000341	0.000835	CcSEcCtD
Paliperidone—Tachycardia—Docetaxel—melanoma	0.00034	0.000832	CcSEcCtD
Paliperidone—Headache—Carmustine—melanoma	0.000339	0.000831	CcSEcCtD
Paliperidone—Skin disorder—Docetaxel—melanoma	0.000338	0.000828	CcSEcCtD
Paliperidone—Vomiting—Temozolomide—melanoma	0.000333	0.000815	CcSEcCtD
Paliperidone—Anorexia—Docetaxel—melanoma	0.000332	0.000813	CcSEcCtD
Paliperidone—Rash—Temozolomide—melanoma	0.00033	0.000809	CcSEcCtD
Paliperidone—Dermatitis—Temozolomide—melanoma	0.00033	0.000808	CcSEcCtD
Paliperidone—Headache—Temozolomide—melanoma	0.000328	0.000803	CcSEcCtD
Paliperidone—Hypotension—Docetaxel—melanoma	0.000325	0.000797	CcSEcCtD
Paliperidone—Nausea—Carmustine—melanoma	0.000322	0.000788	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Docetaxel—melanoma	0.000317	0.000777	CcSEcCtD
Paliperidone—Insomnia—Docetaxel—melanoma	0.000315	0.000771	CcSEcCtD
Paliperidone—Paraesthesia—Docetaxel—melanoma	0.000313	0.000766	CcSEcCtD
Paliperidone—Nausea—Temozolomide—melanoma	0.000311	0.000762	CcSEcCtD
Paliperidone—Dyspnoea—Docetaxel—melanoma	0.00031	0.00076	CcSEcCtD
Paliperidone—Somnolence—Docetaxel—melanoma	0.000309	0.000758	CcSEcCtD
Paliperidone—Dyspepsia—Docetaxel—melanoma	0.000306	0.000751	CcSEcCtD
Paliperidone—Decreased appetite—Docetaxel—melanoma	0.000303	0.000741	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Docetaxel—melanoma	0.0003	0.000736	CcSEcCtD
Paliperidone—Fatigue—Docetaxel—melanoma	0.0003	0.000735	CcSEcCtD
Paliperidone—Pain—Docetaxel—melanoma	0.000298	0.000729	CcSEcCtD
Paliperidone—Constipation—Docetaxel—melanoma	0.000298	0.000729	CcSEcCtD
Paliperidone—Feeling abnormal—Docetaxel—melanoma	0.000287	0.000703	CcSEcCtD
Paliperidone—Gastrointestinal pain—Docetaxel—melanoma	0.000285	0.000697	CcSEcCtD
Paliperidone—Abdominal pain—Docetaxel—melanoma	0.000275	0.000674	CcSEcCtD
Paliperidone—Body temperature increased—Docetaxel—melanoma	0.000275	0.000674	CcSEcCtD
Paliperidone—Hypersensitivity—Docetaxel—melanoma	0.000256	0.000628	CcSEcCtD
Paliperidone—Asthenia—Docetaxel—melanoma	0.00025	0.000612	CcSEcCtD
Paliperidone—Pruritus—Docetaxel—melanoma	0.000246	0.000603	CcSEcCtD
Paliperidone—Diarrhoea—Docetaxel—melanoma	0.000238	0.000584	CcSEcCtD
Paliperidone—Dizziness—Docetaxel—melanoma	0.00023	0.000564	CcSEcCtD
Paliperidone—Vomiting—Docetaxel—melanoma	0.000221	0.000542	CcSEcCtD
Paliperidone—Rash—Docetaxel—melanoma	0.000219	0.000538	CcSEcCtD
Paliperidone—Dermatitis—Docetaxel—melanoma	0.000219	0.000537	CcSEcCtD
Paliperidone—Headache—Docetaxel—melanoma	0.000218	0.000534	CcSEcCtD
Paliperidone—Nausea—Docetaxel—melanoma	0.000207	0.000507	CcSEcCtD
Paliperidone—HRH1—Signaling Pathways—CDKN1B—melanoma	8.95e-06	2.74e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—melanoma	8.95e-06	2.74e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MDM2—melanoma	8.94e-06	2.73e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—HRAS—melanoma	8.94e-06	2.73e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CASP3—melanoma	8.94e-06	2.73e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL2—melanoma	8.92e-06	2.73e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MAPK1—melanoma	8.92e-06	2.73e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EGFR—melanoma	8.92e-06	2.73e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AKT1—melanoma	8.88e-06	2.72e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—melanoma	8.88e-06	2.72e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AKT1—melanoma	8.88e-06	2.71e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—melanoma	8.86e-06	2.71e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—melanoma	8.86e-06	2.71e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—melanoma	8.86e-06	2.71e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CG—melanoma	8.85e-06	2.71e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NRAS—melanoma	8.84e-06	2.7e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ERBB2—melanoma	8.81e-06	2.7e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CASP3—melanoma	8.79e-06	2.69e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1B—melanoma	8.79e-06	2.69e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL2—melanoma	8.78e-06	2.69e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CASP3—melanoma	8.77e-06	2.68e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL2—melanoma	8.76e-06	2.68e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—melanoma	8.75e-06	2.68e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—melanoma	8.74e-06	2.67e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—melanoma	8.72e-06	2.67e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—melanoma	8.71e-06	2.67e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—melanoma	8.7e-06	2.66e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CB—melanoma	8.7e-06	2.66e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—melanoma	8.69e-06	2.66e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—melanoma	8.64e-06	2.64e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CTNNB1—melanoma	8.61e-06	2.63e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CASP3—melanoma	8.61e-06	2.63e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL2—melanoma	8.6e-06	2.63e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—melanoma	8.59e-06	2.63e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—melanoma	8.57e-06	2.62e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—melanoma	8.56e-06	2.62e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—melanoma	8.55e-06	2.62e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—melanoma	8.55e-06	2.62e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—melanoma	8.54e-06	2.61e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—melanoma	8.54e-06	2.61e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARG—melanoma	8.54e-06	2.61e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NRAS—melanoma	8.53e-06	2.61e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—melanoma	8.51e-06	2.6e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NRAS—melanoma	8.49e-06	2.6e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CTNNB1—melanoma	8.48e-06	2.59e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK3—melanoma	8.46e-06	2.59e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CTNNB1—melanoma	8.46e-06	2.59e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—melanoma	8.45e-06	2.58e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—melanoma	8.43e-06	2.58e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—melanoma	8.43e-06	2.58e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1A—melanoma	8.42e-06	2.57e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTEN—melanoma	8.4e-06	2.57e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—melanoma	8.38e-06	2.56e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—melanoma	8.37e-06	2.56e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCL8—melanoma	8.36e-06	2.56e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—melanoma	8.36e-06	2.56e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NFKB1—melanoma	8.36e-06	2.56e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—melanoma	8.31e-06	2.54e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—melanoma	8.3e-06	2.54e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CTNNB1—melanoma	8.3e-06	2.54e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—melanoma	8.29e-06	2.54e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1A—melanoma	8.28e-06	2.53e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—melanoma	8.28e-06	2.53e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1A—melanoma	8.26e-06	2.53e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTEN—melanoma	8.26e-06	2.53e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NRAS—melanoma	8.26e-06	2.52e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTEN—melanoma	8.24e-06	2.52e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTEN—melanoma	8.24e-06	2.52e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—melanoma	8.23e-06	2.52e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—melanoma	8.23e-06	2.52e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NFKB1—melanoma	8.22e-06	2.51e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NFKB1—melanoma	8.2e-06	2.51e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—melanoma	8.19e-06	2.51e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—melanoma	8.19e-06	2.51e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK3—melanoma	8.17e-06	2.5e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1B—melanoma	8.16e-06	2.5e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—melanoma	8.14e-06	2.49e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—melanoma	8.14e-06	2.49e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK3—melanoma	8.13e-06	2.49e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NRAS—melanoma	8.13e-06	2.48e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1A—melanoma	8.11e-06	2.48e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTEN—melanoma	8.09e-06	2.47e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—melanoma	8.07e-06	2.47e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—melanoma	8.06e-06	2.47e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—melanoma	8.06e-06	2.46e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK1—melanoma	8.05e-06	2.46e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—melanoma	8.05e-06	2.46e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NFKB1—melanoma	8.05e-06	2.46e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—melanoma	8.04e-06	2.46e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ABCB1—melanoma	8.02e-06	2.45e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—melanoma	8.01e-06	2.45e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CASP3—melanoma	8e-06	2.45e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL2—melanoma	7.99e-06	2.44e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—melanoma	7.95e-06	2.43e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—melanoma	7.95e-06	2.43e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK3—melanoma	7.91e-06	2.42e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—melanoma	7.91e-06	2.42e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—melanoma	7.89e-06	2.41e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—melanoma	7.85e-06	2.4e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—melanoma	7.84e-06	2.4e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—melanoma	7.81e-06	2.39e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—melanoma	7.79e-06	2.38e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK3—melanoma	7.78e-06	2.38e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CD—melanoma	7.78e-06	2.38e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK1—melanoma	7.77e-06	2.38e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—melanoma	7.77e-06	2.38e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—melanoma	7.74e-06	2.37e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK1—melanoma	7.73e-06	2.37e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—melanoma	7.73e-06	2.36e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—melanoma	7.72e-06	2.36e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CTNNB1—melanoma	7.71e-06	2.36e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—melanoma	7.69e-06	2.35e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ALB—melanoma	7.68e-06	2.35e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—melanoma	7.61e-06	2.33e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—melanoma	7.59e-06	2.32e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—melanoma	7.58e-06	2.32e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—melanoma	7.57e-06	2.31e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—melanoma	7.56e-06	2.31e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1A—melanoma	7.53e-06	2.3e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK1—melanoma	7.52e-06	2.3e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—melanoma	7.52e-06	2.3e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTEN—melanoma	7.52e-06	2.3e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—melanoma	7.51e-06	2.3e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NRAS—melanoma	7.49e-06	2.29e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—melanoma	7.49e-06	2.29e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NFKB1—melanoma	7.48e-06	2.29e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—melanoma	7.46e-06	2.28e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—melanoma	7.45e-06	2.28e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK1—melanoma	7.4e-06	2.26e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—melanoma	7.4e-06	2.26e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—melanoma	7.39e-06	2.26e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—melanoma	7.39e-06	2.26e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PRKCA—melanoma	7.38e-06	2.26e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—melanoma	7.37e-06	2.25e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NRAS—melanoma	7.37e-06	2.25e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NRAS—melanoma	7.35e-06	2.25e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—melanoma	7.34e-06	2.25e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—melanoma	7.33e-06	2.24e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ERCC2—melanoma	7.32e-06	2.24e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—melanoma	7.31e-06	2.23e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—melanoma	7.31e-06	2.23e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—melanoma	7.26e-06	2.22e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—melanoma	7.23e-06	2.21e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—melanoma	7.23e-06	2.21e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NRAS—melanoma	7.22e-06	2.21e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK3—melanoma	7.17e-06	2.19e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—melanoma	7.16e-06	2.19e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—melanoma	7.12e-06	2.18e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—melanoma	7.11e-06	2.17e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK3—melanoma	7.06e-06	2.16e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK3—melanoma	7.04e-06	2.15e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—melanoma	6.99e-06	2.14e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—melanoma	6.99e-06	2.14e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—melanoma	6.98e-06	2.13e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—melanoma	6.95e-06	2.12e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK3—melanoma	6.91e-06	2.11e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—melanoma	6.87e-06	2.1e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—melanoma	6.85e-06	2.1e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—melanoma	6.85e-06	2.1e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK1—melanoma	6.83e-06	2.09e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—melanoma	6.82e-06	2.09e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—melanoma	6.79e-06	2.08e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CB—melanoma	6.78e-06	2.07e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—melanoma	6.76e-06	2.07e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—melanoma	6.75e-06	2.06e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—melanoma	6.72e-06	2.06e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—melanoma	6.72e-06	2.06e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK1—melanoma	6.72e-06	2.05e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—melanoma	6.72e-06	2.05e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—melanoma	6.72e-06	2.05e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—melanoma	6.71e-06	2.05e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NRAS—melanoma	6.71e-06	2.05e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK1—melanoma	6.7e-06	2.05e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—melanoma	6.7e-06	2.05e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK1—melanoma	6.58e-06	2.01e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—melanoma	6.58e-06	2.01e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—melanoma	6.53e-06	2e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—melanoma	6.53e-06	2e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—melanoma	6.49e-06	1.99e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—melanoma	6.47e-06	1.98e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—melanoma	6.45e-06	1.97e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—melanoma	6.42e-06	1.96e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK3—melanoma	6.42e-06	1.96e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—melanoma	6.41e-06	1.96e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—melanoma	6.38e-06	1.95e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—melanoma	6.34e-06	1.94e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—melanoma	6.34e-06	1.94e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—melanoma	6.33e-06	1.94e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—melanoma	6.32e-06	1.93e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—melanoma	6.32e-06	1.93e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—melanoma	6.25e-06	1.91e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—melanoma	6.24e-06	1.91e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—melanoma	6.22e-06	1.9e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—melanoma	6.21e-06	1.9e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—melanoma	6.21e-06	1.9e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—melanoma	6.19e-06	1.89e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK1—melanoma	6.11e-06	1.87e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—melanoma	6.11e-06	1.87e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—melanoma	6.04e-06	1.85e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—melanoma	5.97e-06	1.83e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—melanoma	5.94e-06	1.82e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—melanoma	5.94e-06	1.82e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—melanoma	5.92e-06	1.81e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTEN—melanoma	5.86e-06	1.79e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—melanoma	5.83e-06	1.78e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—melanoma	5.82e-06	1.78e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—melanoma	5.81e-06	1.78e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CG—melanoma	5.78e-06	1.77e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—melanoma	5.78e-06	1.77e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—melanoma	5.77e-06	1.77e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—melanoma	5.73e-06	1.75e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—melanoma	5.71e-06	1.75e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—melanoma	5.71e-06	1.75e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—melanoma	5.69e-06	1.74e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—melanoma	5.64e-06	1.72e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—melanoma	5.63e-06	1.72e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARG—melanoma	5.58e-06	1.71e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—melanoma	5.52e-06	1.69e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—melanoma	5.51e-06	1.69e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—melanoma	5.48e-06	1.68e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—melanoma	5.48e-06	1.68e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—melanoma	5.39e-06	1.65e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—melanoma	5.38e-06	1.65e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—melanoma	5.33e-06	1.63e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—melanoma	5.3e-06	1.62e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—melanoma	5.28e-06	1.61e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—melanoma	5.25e-06	1.61e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—melanoma	5.25e-06	1.6e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—melanoma	5.18e-06	1.58e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—melanoma	5.16e-06	1.58e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—melanoma	5.15e-06	1.57e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—melanoma	5.13e-06	1.57e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CD—melanoma	5.08e-06	1.55e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—melanoma	5.05e-06	1.55e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALB—melanoma	5.02e-06	1.53e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—melanoma	4.91e-06	1.5e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—melanoma	4.84e-06	1.48e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—melanoma	4.76e-06	1.46e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—melanoma	4.75e-06	1.45e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—melanoma	4.75e-06	1.45e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—melanoma	4.7e-06	1.44e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—melanoma	4.66e-06	1.43e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CB—melanoma	4.43e-06	1.36e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—melanoma	4.39e-06	1.34e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—melanoma	4.33e-06	1.32e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—melanoma	4.13e-06	1.26e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTEN—melanoma	3.83e-06	1.17e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—melanoma	3.38e-06	1.03e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—melanoma	2.7e-06	8.26e-06	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—melanoma	2.21e-06	6.75e-06	CbGpPWpGaD
